Evidence map›Paper›PMID 39023121›Full record

ArticleCritical care explorations2024

COVID-19 Across Pandemic Variant Periods: The Severe Acute Respiratory Infection-Preparedness (SARI-PREP) Study.

Vikramjit Mukherjee, Radu Postelnicu, Chelsie Parker, Patrick S Rivers, George L Anesi, Adair Andrews, Erin Ables, Eric D Morrell, David M Brett-Major, M Jana Broadhurst and 18 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care explorations, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Vikramjit MukherjeeDivision of Pulmonary, Critical Care, and Sleep Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York, NY.
Radu PostelnicuDivision of Pulmonary, Critical Care, and Sleep Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York, NY.
Chelsie ParkerDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN.
Patrick S RiversDepartment of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ.
George L AnesiDivision of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Adair AndrewsSociety of Critical Care Medicine, Mount Prospect, IL.
Erin AblesDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN.
Eric D MorrellDivision of Pulmonary, Critical Care and Sleep Medicine, University of Washington School of Medicine, Seattle, WA.
David M Brett-MajorDepartment of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE.
M Jana BroadhurstGlobal Center for Health Security, University of Nebraska Medical Center, Omaha, NE.
J Perren CobbDepartments of Surgery and Anesthesiology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Amy IrwinDivision of Infectious Diseases, Denver Health Medical Center, Denver, CO.
Christopher J KratochvilGlobal Center for Health Security, University of Nebraska Medical Center, Omaha, NE.
Kelsey KrolikowskiDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN.
Vishakha K KumarDivision of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Douglas P LandsittelDepartment of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY.
Richard A LeeDivision of Pulmonary Diseases and Critical Care Medicine, University of California, Irvine, School of Medicine, Irvine, CA.
Janice M LieblerDivision of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Leopoldo N SegalDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN.
Jonathan E SevranskyDivision of Pulmonary, Allergy, Critical Care and Sleep, School of Medicine, Emory University, Atlanta, GA.
Avantika SrivastavaInstitute of Implementation Science in Population Health, City University of New York, New York, NY.
Timothy M UyekiInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA.
Mark M WurfelDivision of Pulmonary, Critical Care and Sleep Medicine, University of Washington School of Medicine, Seattle, WA.
David WylesDivision of Infectious Diseases, Denver Health Medical Center, Denver, CO.
Laura E EvansDivision of Pulmonary, Critical Care and Sleep Medicine, University of Washington School of Medicine, Seattle, WA.
Karen LutrickDepartment of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ.
Pavan K BhatrajuDivision of Pulmonary, Critical Care and Sleep Medicine, University of Washington School of Medicine, Seattle, WA.
Severe Acute Respiratory Infection-Preparedness (SARI-PREP) Study Group

Funding

Identification and Validation of Biological Sub-phenotypes of Sepsis-induced Acute Kidney Injury: A Precision Medicine Approach to Improve Clinical OutcomesR01DK133177 · NIDDK · UNIVERSITY OF WASHINGTON · PI Pavan Kumar Bhatraju · 2022 to 2026
$2.6M
The Role of Alveolar Mononuclear Phagocytes in Acute Respiratory Distress SyndromeK23HL144916 · NHLBI · UNIVERSITY OF WASHINGTON · PI MORRELL, ERIC DOUGLAS · 2019 to 2023
$951k
Hospital adaptation and resiliency for infected and uninfected patients during respiratory viral surge events: from seasonal influenza to COVID-19K23HL161353 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI George L Anesi · 2022 to 2026
$837k
NHLBI NIH HHS K23 HL144916NHLBI NIH HHS K23 HL161353NIDDK NIH HHS R01 DK133177
6 · The paper itself

Abstract

importanceThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has evolved through multiple phases in the United States, with significant differences in patient centered outcomes with improvements in hospital strain, medical countermeasures, and overall understanding of the disease. We describe how patient characteristics changed and care progressed over the various pandemic phases; we also emphasize the need for an ongoing clinical network to improve the understanding of known and novel respiratory viral diseases.

objectivesTo describe how patient characteristics and care evolved across the various COVID-19 pandemic periods in those hospitalized with viral severe acute respiratory infection (SARI).

designSevere Acute Respiratory Infection-Preparedness (SARI-PREP) is a Centers for Disease Control and Prevention Foundation-funded, Society of Critical Care Medicine Discovery-housed, longitudinal multicenter cohort study of viral pneumonia. We defined SARI patients as those hospitalized with laboratory-confirmed respiratory viral infection and an acute syndrome of fever, cough, and radiographic infiltrates or hypoxemia. We collected patient-level data including demographic characteristics, comorbidities, acute physiologic measures, serum and respiratory specimens, therapeutics, and outcomes. Outcomes were described across four pandemic variant periods based on a SARS-CoV-2 sequenced subsample: pre-Delta, Delta, Omicron BA.1, and Omicron post-BA.1.

settingMulticenter cohort of adult patients admitted to an acute care ward or ICU from seven hospitals representing diverse geographic regions across the United States.

participantsPatients with SARI caused by infection with respiratory viruses. MAIN OUTCOMES AND

resultsEight hundred seventy-four adult patients with SARI were enrolled at seven study hospitals between March 2020 and April 2023. Most patients (780, 89%) had SARS-CoV-2 infection. Across the COVID-19 cohort, median age was 60 years (interquartile range, 48.0-71.0 yr) and 66% were male. Almost half (430, 49%) of the study population belonged to underserved communities. Most patients (76.5%) were admitted to the ICU, 52.5% received mechanical ventilation, and observed hospital mortality was 25.5%. As the pandemic progressed, we observed decreases in ICU utilization (94% to 58%), hospital length of stay (median, 26.0 to 8.5 d), and hospital mortality (32% to 12%), while the number of comorbid conditions increased. CONCLUSIONS AND RELEVANCE: We describe increasing comorbidities but improved outcomes across pandemic variant periods, in the setting of multiple factors, including evolving care delivery, countermeasures, and viral variants. An understanding of patient-level factors may inform treatment options for subsequent variants and future novel pathogens.

Indexed as

COVID-19SARS-CoV-2AdultAgedCohort StudiesFemaleHospitalizationHumansIntensive Care UnitsLongitudinal StudiesMaleMiddle AgedPandemicsUnited States

Identifiers

PMID39023121
PMCPMC11259394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.